ESR1 and breast cancer: In BC clinical routine, the assessment of the immunohistochemical biomarkers (IHC), ER, progesterone receptor (PR), and HER2, altogether with the proliferation index (Ki67) is still the widely used protocol to determine the prognosis and eligibility for endocrine, targeted, or cytotoxic therapies [33].